Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review.

Q2 Medicine Therapeutic Advances in Vaccines and Immunotherapy Pub Date : 2022-05-30 eCollection Date: 2022-01-01 DOI:10.1177/25151355221097559
Adekunle Sanyaolu, Chuku Okorie, Aleksandra Marinkovic, Stephanie Prakash, Martina Williams, Nafees Haider, Jasmine Mangat, Zaheeda Hosein, Vyshnavy Balendra, Abu Fahad Abbasi, Priyank Desai, Isha Jain, Stephen Utulor, Amos Abioye
{"title":"Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review.","authors":"Adekunle Sanyaolu, Chuku Okorie, Aleksandra Marinkovic, Stephanie Prakash, Martina Williams, Nafees Haider, Jasmine Mangat, Zaheeda Hosein, Vyshnavy Balendra, Abu Fahad Abbasi, Priyank Desai, Isha Jain, Stephen Utulor, Amos Abioye","doi":"10.1177/25151355221097559","DOIUrl":null,"url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) has made a global impact on the daily lives of humanity, devastating health systems, and cataclysmically affecting the world's economy. Currently, the Standard Public Health Protective practices consist of but are not limited to wearing masks, social distancing, isolating sick and exposed people, and contact tracing. Scientists around the globe undertook swift scientific efforts to develop safe and effective therapeutics and vaccines to combat COVID-19. Presently, as of mid-March 2022, 57.05% of the world population have been fully vaccinated, and 65.3% of the United States of America's (USA) total population have been fully vaccinated while 76.7% have received at least one dose of the vaccine. This article explores the various vaccines created through modern science and technology, including their safety, efficacy, and mechanism of action. Although the vaccines produced are up to 95.0% efficacious, their efficacy wanes over time, underscoring the need for booster doses. Also, vaccination has not been able to prevent \"breakthrough\" infections. The limitations of the SARS-CoV-2 vaccines indicate that further measures are required to ensure a firm control of the COVID-19 pandemic. Therefore, the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the use of certain therapeutic agents because they have shown remarkable clinical outcomes. Several therapeutic agents for the treatment of mild-to-moderate COVID-19 include Gilead's remdesivir, Regeneron's casirivimab and imdevimab combination, Eli Lilly's baricitinib and remdesivir combination, Pfizer's co-packaged nirmatrelvir tablets and ritonavir tablets, and Merck's molnupiravir capsules. Hence concerted efforts in early and accurate diagnosis, education on the COVID-19 virulence, transmission and preventive measures, global vaccination, and therapeutic agents could bring this COVID-19 pandemic under control across the globe.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":" ","pages":"25151355221097559"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160920/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Vaccines and Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25151355221097559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Coronavirus disease 2019 (COVID-19) has made a global impact on the daily lives of humanity, devastating health systems, and cataclysmically affecting the world's economy. Currently, the Standard Public Health Protective practices consist of but are not limited to wearing masks, social distancing, isolating sick and exposed people, and contact tracing. Scientists around the globe undertook swift scientific efforts to develop safe and effective therapeutics and vaccines to combat COVID-19. Presently, as of mid-March 2022, 57.05% of the world population have been fully vaccinated, and 65.3% of the United States of America's (USA) total population have been fully vaccinated while 76.7% have received at least one dose of the vaccine. This article explores the various vaccines created through modern science and technology, including their safety, efficacy, and mechanism of action. Although the vaccines produced are up to 95.0% efficacious, their efficacy wanes over time, underscoring the need for booster doses. Also, vaccination has not been able to prevent "breakthrough" infections. The limitations of the SARS-CoV-2 vaccines indicate that further measures are required to ensure a firm control of the COVID-19 pandemic. Therefore, the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the use of certain therapeutic agents because they have shown remarkable clinical outcomes. Several therapeutic agents for the treatment of mild-to-moderate COVID-19 include Gilead's remdesivir, Regeneron's casirivimab and imdevimab combination, Eli Lilly's baricitinib and remdesivir combination, Pfizer's co-packaged nirmatrelvir tablets and ritonavir tablets, and Merck's molnupiravir capsules. Hence concerted efforts in early and accurate diagnosis, education on the COVID-19 virulence, transmission and preventive measures, global vaccination, and therapeutic agents could bring this COVID-19 pandemic under control across the globe.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19疫苗和治疗方法的当前进展和未来前景:叙述性综述
2019冠状病毒病(COVID-19)对人类的日常生活产生了全球性影响,破坏了卫生系统,并对世界经济产生了灾难性影响。目前,标准公共卫生防护措施包括但不限于戴口罩、保持社交距离、隔离病人和接触者以及追踪接触者。全球科学家迅速开展科学努力,开发安全有效的治疗方法和疫苗来对抗COVID-19。目前,截至2022年3月中旬,世界人口的57.05%已完全接种疫苗,美利坚合众国(美国)总人口的65.3%已完全接种疫苗,76.7%已接种至少一剂疫苗。本文探讨了通过现代科学技术创造的各种疫苗,包括它们的安全性、有效性和作用机制。尽管所生产的疫苗有效率高达95.0%,但其效力随着时间的推移而减弱,这突出了加强剂量的必要性。此外,疫苗接种也未能预防“突破性”感染。SARS-CoV-2疫苗的局限性表明,需要采取进一步措施,确保牢牢控制COVID-19大流行。因此,美国食品和药物管理局(FDA)对某些治疗药物的使用颁发了紧急使用授权(EUA),因为它们已显示出显著的临床效果。用于治疗轻中度COVID-19的几种治疗药物包括吉利德的瑞德西韦、Regeneron的卡西维单抗和imdevimab组合、礼来的baricitinib和瑞德西韦组合、辉瑞的联合包装nirmatrelvir片剂和利托那韦片剂,以及默克的molnupiravir胶囊。因此,在早期准确诊断、关于COVID-19毒力、传播和预防措施的教育、全球疫苗接种和治疗药物等方面的共同努力,可以在全球范围内控制COVID-19大流行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapeutic Advances in Vaccines and Immunotherapy
Therapeutic Advances in Vaccines and Immunotherapy Medicine-Pharmacology (medical)
CiteScore
5.10
自引率
0.00%
发文量
15
审稿时长
8 weeks
期刊最新文献
Rabies post-exposure prophylaxis in India: a SWOT analysis. Exploring the safety and immunogenicity of the VLA15 vaccine among healthy or high-risk population: a systematic review and meta-analysis of randomized controlled trials. Immunization safety monitoring: addressing vaccine hesitancy and enhancing coverage in crisis-affected regions-insights from Lebanon, Ukraine, and Sudan. The urgent need for a licensed dengue vaccine in the Philippines. Uptake of human papillomavirus vaccination and associated factors among high school female students in Dessie City Administration, North East Ethiopia: a cross-sectional study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1